Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Liabilities: 2009-2024

Historic Total Liabilities for Iovance Biotherapeutics (IOVA) over the last 11 years, with Dec 2024 value amounting to $200.0 million.

  • Iovance Biotherapeutics' Total Liabilities rose 126.20% to $202.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.7 million, marking a year-over-year increase of 126.20%. This contributed to the annual value of $200.0 million for FY2024, which is 2.19% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Total Liabilities stood at $200.0 million, which was up 2.19% from $195.7 million recorded in FY2023.
  • Iovance Biotherapeutics' Total Liabilities' 5-year high stood at $200.0 million during FY2024, with a 5-year trough of $195.7 million in FY2023.
  • Its 2-year average for Total Liabilities is $197.9 million, with a median of $197.9 million in 2023.
  • Data for Iovance Biotherapeutics' Total Liabilities shows a peak YoY increased of 2.19% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Total Liabilities (Yearly) stood at $195.7 million in 2023, then climbed by 2.19% to $200.0 million in 2024.